2.43
+0.065(+2.75%)
Currency In USD
| Previous Close | 2.37 |
| Open | 2.34 |
| Day High | 2.49 |
| Day Low | 2.33 |
| 52-Week High | 4.54 |
| 52-Week Low | 0.91 |
| Volume | 1.56M |
| Average Volume | 2.49M |
| Market Cap | 206.81M |
| PE | -1.03 |
| EPS | -2.35 |
| Moving Average 50 Days | 3.14 |
| Moving Average 200 Days | 2.34 |
| Change | 0.07 |
If you invested $1000 in Editas Medicine, Inc. (EDIT) since IPO date, it would be worth $133.52 as of December 04, 2025 at a share price of $2.43. Whereas If you bought $1000 worth of Editas Medicine, Inc. (EDIT) shares 5 years ago, it would be worth $70.46 as of December 04, 2025 at a share price of $2.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
GlobeNewswire Inc.
Oct 09, 2025 3:01 PM GMT
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing com
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming Eu